文献速递支持与姑息治疗

肉芽肿性蕈样肉芽肿新见解:单中心经验

New insights into granulomatous mycosis fungoides (GMF): a single-center experience.
PubMed 文献 · Eur J Cancer · 2021-01-01

该文标题为肉芽肿性蕈样肉芽肿(GMF)的单中心经验,但摘要内容实际报告的是3例Sézary综合征(SS)合并COVID-19患者的回顾性临床数据,未涉及GMF的任何研究结果或结论。

要点

  • 摘要内容与标题不符,实际为SS合并COVID-19的病例报告。
  • 3例SS患者中2例有合并症且需有创机械通气,其中2例死亡。
  • 1例尽管有合并症和有创机械通气仍获良好临床转归。

核心结论

  • 摘要未报告肉芽肿性蕈样肉芽肿的任何研究结论。

研究设计与样本

  • 回顾性收集2020年全球大流行期间在布宜诺斯艾利斯意大利医院皮肤科确诊COVID-19阳性的SS患者的临床数据、SS演变和治疗反应。

主要发现

  • 病例1为58岁男性SS IVA1期,2020年8月因发热、干咳和进行性皮肤病变住院,确诊SARS-CoV-2,在ICU需有创机械通气并全身用糖皮质激素,皮肤病变完全缓解但血液学受累持续,3个月后出院无SARS-CoV-2后遗症。
  • 病例3为86岁男性SS IVA1期,2021年2月因干咳、头痛伴皮肤病变复发住院,实验室检查示既存淋巴细胞减少,确诊SARS-CoV-2,入ICU需有创机械通气,15天后死亡。

局限性

  • 作者指出关于SS患者COVID-19结局的已发表研究有限,多为病例报告,且存在许多未知因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION:: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread worldwide during 2020, was declared as a public health emergency and potentially life-threatening. Patients with hematologic malignancies may have an increased risk of severe COVID-19, due to immunosuppression related to the underlying disease and its treatment. In the absence of specific data, potential risk factors for severe events of COVID-19 should be considered as for other community acquired respiratory virus (CARV) infections: >60 years, severe immunodeficiency, chemotherapy treatment. We present three patients with Sézary syndrome (SS) and COVID-19 infection. OBJECTIVE:: We aim to report the outcome of COVID-19 in patients with SS treated at the department of Dermatology of the Hospital Italiano de Buenos Aires. METHODS AND MATERIAL:: Patients with SS who were diagnosed positive for COVID19 infection, during worldwide pandemic in 2020. We collected retrospectively clinical data, SS evolution and treatment response. CASE 1:: A 58-year-old male with hypertension was diagnosed with SS stage IVA1 in July 2014, he received multiple systemic treatments such as extracorporeal photopheresis (ECP), IFN 2b, bexarotene, with partial response (PR) and eventually stable disease. In August 2020, he was hospitalized due to fever, dry cough and progressive cutaneous disease. SARS-CoV2 was confirmed, requiring invasive mechanical ventilatory (IMV) in the ICU and systemic corticosteroids. The clinical course improved with complete response (CR) of cutaneous disease and persistence of hematologic involvement. He was discharged 3 months later with no SARS-CoV-2 sequels. CASE 2:: A 66-year-old female with breast cancer in 2002 treated with RT and tamoxifeno was diagnosed with SS stage IVA1 in March 2012. She was treated with IFN 2b, TSEB, vorinostat and ECP with CR, relapse and then PR. In November 2020 she started chemotherapy due to cutaneous and nodal progression. A month later, she required hospitalisation and IMV due to dry cough and respiratory distress, SARS-CoV-2 was confirmed. She died 7 days later due to progression of respiratory distress. CASE 3:: An 86-year-old male with arterial hypertension was diagnosed with SS stage IVA1 in March 2017. He received ECP, methotrexate, with PR. In February 2021 he was hospitalized due to dry cough, headache with cutaneous disease relapse. Laboratory parameters showed pre-existing lymphopenia. SARS CoV-2 was confirmed. He was admitted to the ICU requiring IMV due to respiratory distress, and died 15 days after. CONCLUSIONS:: Among our patients, two had several associated comorbidities and risk factors for a severe event of COVID-19, besides case 3 presented pre-existing lymphopenia at presentation. Case 1, despite his comorbidities and IMV, developed a favorable clinical course. To our knowledge there are many unknown factors and limited published studies, describing COVID-19 outcomes in patients with SS, most of them based on case reports.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Sidiropoulou P, Tsaoutou K, Constantinou A, et al. New insights into granulomatous mycosis fungoides (GMF): a single-center experience. Eur J Cancer. 2021. PMID: 34649669. doi:10.1016/S0959-8049(21)00757-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。